54 research outputs found
Eclesiásticos entre los pensionados y científicos de la junta para ampliación de estudios, II
In a previous article (Hispania Sacra, n. 103), we tried to confirm if there was discrimination in favour of the priests of the Junta para Ampliación de Estudios (JPA). We showed that there was no discrimination, but we had only analysed a small number of cases. In this article, we complete the first one bi analysing the case of every priest who asked for a grant from the JPA received it, of those who obtained a grant recognition and of those who worked it, of those who obtained a grant recognition and of those who worked in any center of the JPA. Once again, our conclusion is that there was no discrimination at all.En un artículo publicado en el n° 103 de Hispania Sacra nos planteábamos si hubo o no discriminación por parte de la Junta para Ampliación de Estudios hacia los clérigos, por el mero hecho de serlo. Concluíamos entonces que no la hubo, pero el sondeo era pequeño. En el presente artículo, continuación de aquel primero, analizaremos la totalidad de los clérigos que solicitaron pensión y fueron pensionados por la Junta, así como aquellos clérigos que obtuvieron una consideración de pensión y aquellos otros que trabajaron en alguno de los centros de investigación de este organismo, y de nuevo concluiremos que no hubo tal discriminación
Eclesiásticos entre los pensionados y científicos de la junta para ampliación de estudios, II
In a previous article (Hispania Sacra, n. 103), we tried to confirm if there was discrimination in favour of the priests of the Junta para Ampliación de Estudios (JPA). We showed that there was no discrimination, but we had only analysed a small number of cases. In this article, we complete the first one bi analysing the case of every priest who asked for a grant from the JPA received it, of those who obtained a grant recognition and of those who worked it, of those who obtained a grant recognition and of those who worked in any center of the JPA. Once again, our conclusion is that there was no discrimination at all.En un artículo publicado en el n° 103 de Hispania Sacra nos planteábamos si hubo o no discriminación por parte de la Junta para Ampliación de Estudios hacia los clérigos, por el mero hecho de serlo. Concluíamos entonces que no la hubo, pero el sondeo era pequeño. En el presente artículo, continuación de aquel primero, analizaremos la totalidad de los clérigos que solicitaron pensión y fueron pensionados por la Junta, así como aquellos clérigos que obtuvieron una consideración de pensión y aquellos otros que trabajaron en alguno de los centros de investigación de este organismo, y de nuevo concluiremos que no hubo tal discriminación
The TechnoFusion Consortium of Spanish institutions and facilities towards the development of fusion materials and related technologies in Europe
14 pags., 10 figs.With the objective of contributing to the European development of materials, technologies and facilities for the demonstration of the thermonuclear fusion, the construction of the unique TechnoFusión facility was planned in 2009. The TechnoFusión consortium, formed by selected Spanish research groups and laboratories located in Madrid, has jointly advanced in the search for solutions to the remaining technological issues of nuclear fusion by magnetic and inertial confinement. In addition, the foundation of the TechnoFusión partnership has been essential to create a network of collaborations, and also to expand and specialize human resources, by training scientists and technical staff in the use of high-tech tools. Supported by the TechnoFusión_Comunidad Madrid (III) regional programme, the consortium is focused on providing support for the construction of medium-sized, relevant facilities in Madrid (Spain). Regarding magnetic and inertial fusion issues, the programme is structured in several key experiments and infrastructures, which combine the development of materials, of cutting-edge technologies and the construction of associated facilities, with the progress in simulation and application of computational neutronics:The authors acknowledge the funding by Community of Madrid, co-financed with Structural Funds (ERDF and ESF)), through the TechnoFusión (III)-CM (S2018/EMT-4437) programme. This work has also been carried out within the framework of the EUROfusion Consortium and has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement number 633053. The views and opinions expressed in this document do not necessarily reflect those of the European Commission. In particular, R. González-Arrabal acknowledges the Convenio Plurianual con la Universidad Politécnica de Madrid en la línea de actuación Programa de Excelencia para el Profesorado Universitario of the CAM (Comunidad Autónoma Madrid)
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters.
Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs).
Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001).
Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio
COVID-19 vaccine failure
COVID-19 affects the population unequally with a higher impact on aged and
immunosuppressed people. Hence, we assessed the effect of SARS-CoV-2 vaccination
in immune compromised patients (older adults and oncohematologic patients),
compared with healthy counterparts. While the acquired humoral and cellular memory
did not predict subsequent infection 18 months after full immunization, spectral and
computational cytometry revealed several subsets within the CD8+ T-cells, B-cells, NK
cells, monocytes and CD45RA+
CCR7- Tγδ cells differentially expressed in further
infected and non-infected individuals not just following immunization, but also prior to
that. Of note, up to 7 subsets were found within the CD45RA+
CCR7-
Tγδ population with
some of them being expanded and other decreased in subsequently infected individuals.
Moreover, some of these subsets also predicted COVID-induced hospitalization in
oncohematologic patients. Therefore, we hereby have identified several cellular subsets
that, even before vaccination, strongly related to COVID-19 vulnerability as opposed to
the acquisition of cellular and/or humoral memory following vaccination with SARS-CoV2 mRNA vaccines.This study has been funded through Programa Estratégico Instituto de Biología y
Genética Molecular (IBGM Junta de Castilla y León. Ref. CCVC8485), Junta de Castilla
y León (Proyectos COVID 07.04.467B04.74011.0) and the European Commission –
NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform
(PTI Salud Global; SGL21-03-026 and SGL2021-03-038)N
Recommended from our members
Dietary α‐Linolenic Acid, Marine ω‐3 Fatty Acids, and Mortality in a Population With High Fish Consumption: Findings From the PREvención con DIeta MEDiterránea (PREDIMED) Study
Background: Epidemiological evidence suggests a cardioprotective role of α‐linolenic acid (ALA), a plant‐derived ω‐3 fatty acid. It is unclear whether ALA is beneficial in a background of high marine ω‐3 fatty acids (long‐chain n‐3 polyunsaturated fatty acids) intake. In persons at high cardiovascular risk from Spain, a country in which fish consumption is customarily high, we investigated whether meeting the International Society for the Study of Fatty Acids and Lipids recommendation for dietary ALA (0.7% of total energy) at baseline was related to all‐cause and cardiovascular disease mortality. We also examined the effect of meeting the society's recommendation for long‐chain n‐3 polyunsaturated fatty acids (≥500 mg/day). Methods and Results: We longitudinally evaluated 7202 participants in the PREvención con DIeta MEDiterránea (PREDIMED) trial. Multivariable‐adjusted Cox regression models were fitted to estimate hazard ratios. ALA intake correlated to walnut consumption (r=0.94). During a 5.9‐y follow‐up, 431 deaths occurred (104 cardiovascular disease, 55 coronary heart disease, 32 sudden cardiac death, 25 stroke). The hazard ratios for meeting ALA recommendation (n=1615, 22.4%) were 0.72 (95% CI 0.56–0.92) for all‐cause mortality and 0.95 (95% CI 0.58–1.57) for fatal cardiovascular disease. The hazard ratios for meeting the recommendation for long‐chain n‐3 polyunsaturated fatty acids (n=5452, 75.7%) were 0.84 (95% CI 0.67–1.05) for all‐cause mortality, 0.61 (95% CI 0.39–0.96) for fatal cardiovascular disease, 0.54 (95% CI 0.29–0.99) for fatal coronary heart disease, and 0.49 (95% CI 0.22–1.01) for sudden cardiac death. The highest reduction in all‐cause mortality occurred in participants meeting both recommendations (hazard ratio 0.63 [95% CI 0.45–0.87]). Conclusions: In participants without prior cardiovascular disease and high fish consumption, dietary ALA, supplied mainly by walnuts and olive oil, relates inversely to all‐cause mortality, whereas protection from cardiac mortality is limited to fish‐derived long‐chain n‐3 polyunsaturated fatty acids. Clinical Trial Registration URL: http://www.Controlled-trials.com/. Unique identifier: ISRCTN35739639
Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study
Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat
Recommended from our members
Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study
Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat
Recommended from our members
Correction to: Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study
The original version of this article unfortunately contained a mistake
- …